HSBC Holdings’s Biogen BIIB Stock Holding History

HSBC Holdings’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-26,800	Closed	-$4.72M	–	2920
2025 Q4	$4.72M	Buy	26,800 +20,800	+347%	+$3.4M	﹤0.01%	1233
2025 Q3	$840K	Buy	6,000 +3,500	+140%	+$473K	﹤0.01%	1872
2025 Q2	$314K	Hold	2,500	–	–	﹤0.01%	2411
2025 Q1	$342K	Sell	2,500 -8,000	-76%	-$1.14M	﹤0.01%	2301
2024 Q4	$1.6M	Buy	10,500 +6,000	+133%	+$1.01M	﹤0.01%	1568
2024 Q3	$872K	Sell	4,500 -11,000	-71%	-$2.3M	﹤0.01%	1759
2024 Q2	$3.55M	Buy	15,500 +500	+3%	+$109K	﹤0.01%	1181
2024 Q1	$3.23M	Buy	15,000 +1,500	+11%	+$351K	﹤0.01%	1279
2023 Q4	$3.49M	Sell	13,500 -2,000	-13%	-$491K	﹤0.01%	1281
2023 Q3	$4M	Buy	15,500 +7,500	+94%	+$2.01M	﹤0.01%	1168
2023 Q2	$2.26M	Sell	8,000 -500	-6%	-$149K	﹤0.01%	1396
2023 Q1	$2.34M	Sell	8,500 -8,000	-48%	-$2.21M	﹤0.01%	1445
2022 Q4	$4.55M	Buy	16,500 +3,000	+22%	+$847K	0.01%	1295
2022 Q3	$3.62M	Sell	13,500 -3,700	-22%	-$786K	0.01%	1308
2022 Q2	$3.55M	Sell	17,200 -3,800	-18%	-$777K	0.01%	1326
2022 Q1	$4.45M	Buy	21,000 +1,300	+7%	+$283K	0.01%	1224
2021 Q4	$4.76M	Buy	19,700 +6,800	+53%	+$1.75M	﹤0.01%	1278
2021 Q3	$3.67M	Buy	12,900 +10,300	+396%	+$3.38M	﹤0.01%	1289
2021 Q2	$900K	Sell	2,600 -2,000	-43%	-$606K	﹤0.01%	1823
2021 Q1	$1.29M	Buy	4,600 +3,400	+283%	+$917K	﹤0.01%	1477
2020 Q4	$294K	Sell	1,200 -9,900	-89%	-$2.55M	﹤0.01%	2577
2020 Q3	$3.14M	Buy	11,100 +1,900	+21%	+$530K	0.01%	1127
2020 Q2	$2.46M	Sell	9,200 -32,200	-78%	-$9.68M	﹤0.01%	1105
2020 Q1	$12.9M	Buy	41,400 +28,200	+214%	+$8.56M	0.03%	497
2019 Q4	$3.91M	Sell	13,200 -21,800	-62%	-$6.05M	0.01%	1206
2019 Q3	$8.15M	Sell	35,000 -5,200	-13%	-$1.21M	0.02%	953
2019 Q2	$9.4M	Buy	40,200 +15,200	+61%	+$3.51M	0.02%	857
2019 Q1	$5.91M	Sell	25,000 -16,200	-39%	-$5.1M	0.01%	1043
2018 Q4	$12.4M	Buy	41,200 +11,800	+40%	+$3.77M	0.02%	713
2018 Q3	$10.4M	Buy	29,400 +9,300	+46%	+$3.2M	0.02%	846
2018 Q2	$5.83M	Buy	20,100 +3,400	+20%	+$956K	0.01%	1049
2018 Q1	$4.57M	Buy	16,700 +12,700	+318%	+$3.94M	0.01%	1138
2017 Q4	$1.27M	Sell	4,000 -2,800	-41%	-$898K	﹤0.01%	1225
2017 Q3	$2.13M	Buy	6,800 +3,800	+127%	+$1.13M	﹤0.01%	1289
2017 Q2	$814K	Sell	3,000 -2,000	-40%	-$529K	﹤0.01%	1521
2017 Q1	$1.37M	Sell	5,000 -24,500	-83%	-$6.93M	﹤0.01%	1335
2016 Q4	$8.37M	Buy	29,500 +10,500	+55%	+$3.11M	0.02%	779
2016 Q3	$5.95M	Buy	+19,000	New	+$5.63M	0.01%	855
2016 Q2	–	Sell	-30,000	Closed	-$7.81M	–	2053
2016 Q1	$7.81M	Buy	30,000 +18,700	+165%	+$4.94M	0.02%	738
2015 Q4	$3.46M	Buy	+11,300	New	+$3.25M	0.01%	1073
2015 Q3	–	Sell	-956	Closed	-$386K	–	1944
2015 Q2	$386K	Sell	956 -3,544	-79%	-$1.42M	﹤0.01%	1508
2015 Q1	$1.9M	Sell	4,500 -8,300	-65%	-$3.27M	﹤0.01%	1184
2014 Q4	$4.34M	Buy	12,800 +1,600	+14%	+$518K	0.01%	938
2014 Q3	$3.71M	Buy	11,200 +10,000	+833%	+$3.3M	0.01%	979
2014 Q2	$378K	Hold	1,200	–	–	﹤0.01%	1549
2014 Q1	$367K	Buy	+1,200	New	+$381K	﹤0.01%	1481

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HSBC Holdings's BIIB Position: Q1 2026 in Review

HSBC Holdings reduced its Biogen (BIIB) stake by 8% in Q1 2026, selling an estimated $7.4M and leaving 463,652 shares worth $84.6M. The position accounts for 0.04% of the portfolio, ranked #378.

HSBC Holdings first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $166M in Q1 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

HSBC Holdings held 463,652 shares of Biogen worth $84.6M as of Q1 2026.
HSBC Holdings sold 40,180 Biogen shares in Q1 2026, an estimated $7.4M.
Biogen made up 0.04% of HSBC Holdings's portfolio in Q1 2026, its #378 holding.
HSBC Holdings first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
HSBC Holdings's Biogen position peaked at $166M in Q1 2015.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.